But several funds may already be racking up big gains in March.
Stephen TaubMarch 16, 2023
Amir Hamja/Bloomberg
Biopharma hedge funds turned in generally weak performances in February. After a fairly strong January, most of the funds lost money for the month, and this pushed several of the funds back into the red for
To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.